{"result": "(\"entity\"<|>NEOPLASIAS FOLICULARES<|>EVENT<|>Neoplasias foliculares are a type of thyroid tumor that can be benign or malignant, often requiring careful evaluation and management.)\n##\n(\"entity\"<|>TIROGLOBULINA<|>EVENT<|>Tiroglobulina is a protein produced by the thyroid gland, used as a tumor marker in monitoring thyroid cancer patients.)\n##\n(\"entity\"<|>HÜRTHLE CELLS<|>EVENT<|>Hürthle cells are a type of thyroid cell that can appear in tumors and are categorized independently in thyroid pathology.)\n##\n(\"relationship\"<|>NEOPLASIAS FOLICULARES<|>TIROIDES<|>Neoplasias foliculares occur in the thyroid gland and can be associated with both benign and malignant conditions.<|>7)\n##\n(\"relationship\"<|>TIROGLOBULINA<|>ANTICUERPOS ANTITIROGLOBULINA<|>The presence of anticuerpos antitiroglobulina can interfere with the measurement of tiroglobulina, complicating the assessment of thyroid cancer recurrence.<|>6)\n##\n(\"relationship\"<|>HÜRTHLE CELLS<|>TIROIDES<|>Hürthle cells are a specific type of cell found in the thyroid gland and can be involved in certain thyroid tumors.<|>7)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ician de la ablación\n               de 2017:                                                                                                                                   con I-131.\n               A. Los tumores de potencial maligno incierto son neoplasias de patrón folicular bien                                                   B. En los tumores con riesgo alto de recidiva, la TSH se debe mantener inicialmente por\n                    delimitadas, con dudosa invasión capsular o vascular.                                                                                 debajo de 0,1 mUI/l.\n               B. Los tumores de potencial maligno incierto en general deben ser abordados como                                                       C. La positividad de los anticuerpos antitiroglobulina interfiere con la utilidad de la\n                    benignos.                                                                                                                             determinación de tiroglobulina en el seguimiento de estos pacientes.\n               C. Las neoplasias foliculares no invasivas con características nucleares sugestivas de tipo                                            D.  La ablación con I-131 se recomienda en los tumores con riesgo alto de recidiva.\n                    papilar en general deben ser abordadas como malignas.\n               D.   Los tumores de células de Hürthle aparecen como categoría independiente con respecto\n                    a los tumores foliculares.\n\n\n\n174                                                                                                                                                                                                                                                                                    175\n---\n                                                                                                                                                                                                                                                                     TIROIDES  3\n\n\n\n     COMENTARIO                                                                                                                                              39  En un paciente con carcinoma papilar de tiroides en tratamiento con tiroxina en\n     Para planificar el seguimiento de los carcinomas diferenciados de tiroides después de la                                                                    dosis sustitutiva (TSH 1,7 mUl/ml) se objetiva una tiroglobulina de 2,1 ng/ml con\n     cirugía inicial es fundamental su estratificación según el riesgo de recidiva: aquellos carci-                                                              anticuerpos antitiroglobulina negativos. Tras estímulo con TSHhr (TSH > 80 mUl/\n     nomas con mayor riesgo se beneficiarán de un seguimiento más estrecho y de una actitud                                                                      ml), el rastreo con 113l es negativo y la tiroglobulina estimulada es de 17,6 ng/ml\n     más agresiva durante su seguimiento.                                                                                                                        con anticuerpos antitiroglobulina negativos. En esta situación, ¿cuál de las\n     Así, a la hora de valorar un tratamiento con I-131 para eliminar posibles restos tiroideos                                                                  siguientes afirmaciones es falsa?\n     (tratamiento ablativo), las guías de práctica clínica más comúnmente aceptadas recomien-                                                                    A. Hay un 30% de posibilidades de que evolucione espontáneamentea la normalización.\n     dan su utilización en caso de riesgo alto de recidiva (Guía ATA 2015 para el manejo de los                                                                  B. No requiere ninguna medida adicional de tratamiento ni de seguimiento, solo observación\n     nódulos tiroideos y carcinoma diferenciado de tiroides), mientras que en                                                           caso      de riesgo            regular.\n     bajo de recidiva no lo recomiendan. Por lo tanto, la opción A de la pregunta es falsa, mien-                                                                C. Hay un 20% de posibilidades de recurrencia estructural.\n     tras que la D es verdadera.                                                                                                                                 D.    En este caso, el riesgo de mortalidad específica por cáncer de tiroides es inferior a un 1%.\n     El mismo concepto de individualización del seguimiento según el riesgo de recidiva se apli-\n     ca a la intensidad de la supresión de la TSH endógena, de forma que cuanto mayor sea el\n     riesgo de recidiva más bajo deberían mantenerse los niveles de TSH. En los casos de riesgo                                                                  COMENTARIO\n     alto de recidiva se recomienda que la TSH se mantenga entre 0,1 y 0,5 mUI/l durante los 5                                                                   La situación del paciente referido puede catalogarse como una respuesta bioquímica in-\n     primeros años.                                                                                                                                              completa, ya que no hay evidencia estructural de tumor, pero los niveles de tiroglobulina\n     Finalmente, es bien                 conocido que             la presencia de anticuerpos                        antitiroglobulina interfiere                que presenta son claramente elevados. Concretamente se define esta categoría cuando la\n     en la determinación de la tiroglobulina plasmática, por lo que todas las guías de práctica                                                                  tiroglobulina con TSH suprimida es igual o superior a 1 ng/ml o estimulada igual o superior\n     clínica recomiendan su determinación sistemática junto a la tiroglobulina.                                                                                  a 10 ng/ml, siempre con Ac. antitiroglobulina negativos, como es el caso que nos ocupa.\n                                                                                                                                                                 La evolución a largo plazo de los pacientes encuadrados en esta categoría de respuesta al\n                                                                                                                               En caso de riesgo alto de         tratamiento es variable, pudiendo presentar una recidiva estructural tumoral, lo que sucede\n                                                                                                                                       recidiva                  en aproximadamente un 20%, pero también, hasta en un 30% de los casos, puede evolu-\n              Respuesta estructural incompleta                                                 Supresión completa\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>I-131<|>EVENT<|>I-131 is a radioactive isotope used in the treatment of thyroid cancer, particularly for ablating thyroid tissue after surgery.)\n##\n(\"entity\"<|>TIROIDES<|>GEO<|>Tiroides refers to the thyroid gland, which is involved in the production of hormones that regulate metabolism and is the site of various cancers.)\n##\n(\"entity\"<|>CARCINOMA PAPILAR<|>EVENT<|>Carcinoma papilar is a type of thyroid cancer that is generally considered to have a good prognosis and is treated with surgery and radioactive iodine.)\n##\n(\"entity\"<|>TSH<|>EVENT<|>TSH, or Thyroid Stimulating Hormone, is a hormone that regulates the production of thyroid hormones and is crucial in monitoring thyroid cancer treatment.)\n##\n(\"entity\"<|>ANTICUERPOS ANTITIROGLOBULINA<|>EVENT<|>Anticuerpos antitiroglobulina are antibodies that can interfere with the measurement of thyroglobulin, which is used to monitor thyroid cancer recurrence.)\n##\n(\"entity\"<|>GUÍA ATA 2015<|>EVENT<|>Guía ATA 2015 is a clinical practice guideline for the management of thyroid nodules and differentiated thyroid cancer, providing recommendations for treatment and follow-up.)\n##\n(\"relationship\"<|>CARCINOMA PAPILAR<|>TIROIDES<|>Carcinoma papilar is a type of cancer that occurs in the thyroid gland, affecting its function and health.<|>8)\n##\n(\"relationship\"<|>I-131<|>CARCINOMA PAPILAR<|>I-131 is commonly used in the treatment of carcinoma papilar to eliminate remaining thyroid tissue after surgery.<|>9)\n##\n(\"relationship\"<|>TSH<|>CARCINOMA PAPILAR<|>TSH levels are monitored in patients with carcinoma papilar to assess the risk of recurrence and guide treatment decisions.<|>7)\n##\n(\"relationship\"<|>ANTICUERPOS ANTITIROGLOBULINA<|>TSH<|>The presence of anticuerpos antitiroglobulina can interfere with TSH measurements, complicating the monitoring of thyroid cancer patients.<|>6)\n##\n(\"relationship\"<|>GUÍA ATA 2015<|>CARCINOMA PAPILAR<|>Guía ATA 2015 provides guidelines for the management and follow-up of patients with carcinoma papilar, influencing treatment protocols.<|>8)\n<|COMPLETE|>"}]}